To The Moon
Home
News
TigerAI
Log In
Sign Up
shiyotham
+Follow
Posts · 8
Posts · 8
Following · 0
Following · 0
Followers · 0
Followers · 0
shiyotham
shiyotham
·
2021-06-23
Fair competition I guess
Sorry, this post has been deleted
看
1.56K
回复
2
点赞
3
编组 21备份 2
Share
Report
shiyotham
shiyotham
·
2021-06-16
Awesome!
Sorry, this post has been deleted
看
972
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
shiyotham
shiyotham
·
2021-06-15
Good read
These energy and EV stocks can still benefit from Biden's infrastructure plan, Citi says
Critical information for the trading day. U.S. stocks got off to a mixed start on Monday, after the
These energy and EV stocks can still benefit from Biden's infrastructure plan, Citi says
看
1.23K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
shiyotham
shiyotham
·
2021-06-15
Yes to effective vaccines!
Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
It was "better late than never" for Novavax, Inc.NVAX, as the biopharma finally got around to announ
Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
看
1.17K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
shiyotham
shiyotham
·
2021-06-11
? ??
Sorry, this post has been deleted
看
1.20K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
shiyotham
shiyotham
·
2021-06-11
Nio ftw ??
Sorry, this post has been deleted
看
1.31K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
shiyotham
shiyotham
·
2021-06-07
The next GameStop!
Sorry, this post has been deleted
看
1.43K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
shiyotham
shiyotham
·
2021-06-07
[Doubt]
Sorry, this post has been deleted
看
1.12K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3581911525047676","uuid":"3581911525047676","gmtCreate":1618817977778,"gmtModify":1720792370385,"name":"shiyotham","pinyin":"shiyotham","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/ffd7475c753c52dc5527673c8bc28362","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":12,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"80.48%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":2,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":121673797,"gmtCreate":1624463736319,"gmtModify":1703837630820,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"shiyotham","avatar":"https://community-static.tradeup.com/news/ffd7475c753c52dc5527673c8bc28362","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Fair competition I guess","listText":"Fair competition I guess","text":"Fair competition I guess","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/121673797","repostId":"1145825451","repostType":4,"isVote":1,"tweetType":1,"viewCount":1556,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169761044,"gmtCreate":1623851274988,"gmtModify":1703821388666,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"shiyotham","avatar":"https://community-static.tradeup.com/news/ffd7475c753c52dc5527673c8bc28362","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Awesome!","listText":"Awesome!","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169761044","repostId":"1175265723","repostType":4,"isVote":1,"tweetType":1,"viewCount":972,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187461331,"gmtCreate":1623762201623,"gmtModify":1703818494283,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"shiyotham","avatar":"https://community-static.tradeup.com/news/ffd7475c753c52dc5527673c8bc28362","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187461331","repostId":"2143735244","repostType":4,"repost":{"id":"2143735244","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623750480,"share":"https://ttm.financial/m/news/2143735244?lang=en_US&edition=fundamental","pubTime":"2021-06-15 17:48","market":"hk","language":"en","title":"These energy and EV stocks can still benefit from Biden's infrastructure plan, Citi says","url":"https://stock-news.laohu8.com/highlight/detail?id=2143735244","media":"Dow Jones","summary":"Critical information for the trading day.\n\nU.S. stocks got off to a mixed start on Monday, after the","content":"<blockquote>\n Critical information for the trading day.\n</blockquote>\n<p>U.S. stocks got off to a mixed start on Monday, after the S&P 500 notched its 28th record high of the year on Friday.</p>\n<p>Investors will be closely watching the Federal Reserve's latest monetary policy decision on Wednesday as well as what Chair Jerome Powell has to say .</p>\n<p>President Joe Biden's infrastructure plans are also in focus, after talks with Senate Republicans over a $1.7 trillion deal collapsed last week. Bipartisan efforts over a compromise are continuing, while a Democratic-only Reconciliation Bill is also seen as an option. Biden has set a summer deadline for Congress to pass his top legislative priority.</p>\n<p>In our call of the day, Citi strategists looked at the prospects for Biden's infrastructure plans and the stocks that are likely to benefit.</p>\n<p>The strategists, led by Edward Morse, said it now looked likely that passable legislation would be below the $1.7 trillion of infrastructure but higher than $1 trillion. The team looked at which areas would still make the cut in terms of spending.</p>\n<p>\"Enhanced policy support for carbon capture, utilization and storage (CCUS) likely survives and would have bipartisan support if a reconciliation process fails,\" they said.</p>\n<p>CCUS involves capturing carbon dioxide from large sources, such as power plants, and storing it to be recycled. It can play an \"important and diverse\" role in meeting global energy and climate goals, according to the International Energy Agency.</p>\n<p>\"The bill could jump-start an industry that could grow to be larger than today's domestic oil-and-gas industry,\" Citi strategists said. That would change the terminal value debate over companies such as Exxon Mobil <a href=\"https://laohu8.com/S/XOM\">$(XOM)$</a>, which has more than 30 years of experience in CCUS, and other established names in the space, including Baker Hughes <a href=\"https://laohu8.com/S/BKR\">$(BKR)$</a>, Schlumberger <a href=\"https://laohu8.com/S/SLB\">$(SLB)$</a>, Chart Industries <a href=\"https://laohu8.com/S/GTLS\">$(GTLS)$</a>, Valero Energy <a href=\"https://laohu8.com/S/VLO\">$(VLO)$</a> and Kinder Morgan <a href=\"https://laohu8.com/S/KMI\">$(KMI)$</a>, they added.</p>\n<p>Renewables adoption is also poised to accelerate, they said, with the demand for clean energy boosted by Biden's agenda on climate change. It could potentially lead to significant investments in existing renewable facilities and building new solar and wind farms.</p>\n<p>\"We think this bodes well for specialty contractors, such as MasTec <a href=\"https://laohu8.com/S/MTZ\">$(MTZ)$</a> and engineering and construction-focused Fluor <a href=\"https://laohu8.com/S/FLR\">$(FLR)$</a> given their expertise in clean energy infrastructure and management, as well as for General Electric <a href=\"https://laohu8.com/S/GE\">$(GE)$</a> given its wind turbine portfolio and related digital offerings,\" they said.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other long-term themes to watch out for are electric-vehicle infrastructure and green hydrogen, which is produced when renewable energy powers the electrolysis of water -- breaking it into its component elements of hydrogen and oxygen.</p>\n<p>MasTec, Rockwell Automation <a href=\"https://laohu8.com/S/ROK\">$(ROK)$</a>, 3M <a href=\"https://laohu8.com/S/MMM\">$(MMM)$</a>, Vontier <a href=\"https://laohu8.com/S/VNT\">$(VNT)$</a> and Dover Corp <a href=\"https://laohu8.com/S/DOV\">$(DOV)$</a> are all set to benefit from EV proliferation, while General Electric, Emerson Electric <a href=\"https://laohu8.com/S/EMR\">$(EMR)$</a> and KBR <a href=\"https://laohu8.com/S/KBR\">$(KBR)$</a> can capitalize on the emergence of green hydrogen, they added.</p>\n<p><b>The markets</b></p>\n<p>European stocks climbed to fresh record highs on Monday as inflation fears continued to ease. U.S. stocks were mixed in early trading . The yield on the 10-year Treasury remained anchored below 1.50%.</p>\n<p><b>The tweet</b></p>\n<p>Bitcoin jumped sharply on Sunday Chief Executive Elon Musk said the electric-vehicle company \"only\" sold around 10% of its holdings and would resume allowing transactions using the cryptocurrency when 50% of energy used to mine it comes from clean sources. Bitcoin was trading at $39,507.35 early on Friday and has climbed 11.7% in the past 24 hours, according to CoinDesk.</p>\n<p><b>The buzz</b></p>\n<p>Royal Dutch Shell is reviewing its holdings in the largest oil field in the U.S . -- the Permian Basin, mostly in Texas -- according to reports on Sunday. A sale could raise up to $10 billion, CNBC said.</p>\n<p>U.K. Prime Minister Boris Johnson is expected to confirm a four-week delay to the next planned relaxation of COVID-19 restrictions in England due to the spread of the delta coronavirus variant.</p>\n<p>Leaders of the G-7 (Group of Seven) countries rallied around Biden's call to challenge China over human rights and vowed to donate <a href=\"https://laohu8.com/S/AONE\">one</a> billion COVID-19 vaccine doses to poorer nations over the next year.</p>\n<p>Novavax <a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a> reported that a Phase 3 study of its COVID-19 vaccine showed it was 90.4% effective overall . The 29,960-patient study also found that the vaccine provided 100% protection against moderate and severe disease. The biotech intends to file for regulatory authorizations in the third quarter.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These energy and EV stocks can still benefit from Biden's infrastructure plan, Citi says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese energy and EV stocks can still benefit from Biden's infrastructure plan, Citi says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-15 17:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n Critical information for the trading day.\n</blockquote>\n<p>U.S. stocks got off to a mixed start on Monday, after the S&P 500 notched its 28th record high of the year on Friday.</p>\n<p>Investors will be closely watching the Federal Reserve's latest monetary policy decision on Wednesday as well as what Chair Jerome Powell has to say .</p>\n<p>President Joe Biden's infrastructure plans are also in focus, after talks with Senate Republicans over a $1.7 trillion deal collapsed last week. Bipartisan efforts over a compromise are continuing, while a Democratic-only Reconciliation Bill is also seen as an option. Biden has set a summer deadline for Congress to pass his top legislative priority.</p>\n<p>In our call of the day, Citi strategists looked at the prospects for Biden's infrastructure plans and the stocks that are likely to benefit.</p>\n<p>The strategists, led by Edward Morse, said it now looked likely that passable legislation would be below the $1.7 trillion of infrastructure but higher than $1 trillion. The team looked at which areas would still make the cut in terms of spending.</p>\n<p>\"Enhanced policy support for carbon capture, utilization and storage (CCUS) likely survives and would have bipartisan support if a reconciliation process fails,\" they said.</p>\n<p>CCUS involves capturing carbon dioxide from large sources, such as power plants, and storing it to be recycled. It can play an \"important and diverse\" role in meeting global energy and climate goals, according to the International Energy Agency.</p>\n<p>\"The bill could jump-start an industry that could grow to be larger than today's domestic oil-and-gas industry,\" Citi strategists said. That would change the terminal value debate over companies such as Exxon Mobil <a href=\"https://laohu8.com/S/XOM\">$(XOM)$</a>, which has more than 30 years of experience in CCUS, and other established names in the space, including Baker Hughes <a href=\"https://laohu8.com/S/BKR\">$(BKR)$</a>, Schlumberger <a href=\"https://laohu8.com/S/SLB\">$(SLB)$</a>, Chart Industries <a href=\"https://laohu8.com/S/GTLS\">$(GTLS)$</a>, Valero Energy <a href=\"https://laohu8.com/S/VLO\">$(VLO)$</a> and Kinder Morgan <a href=\"https://laohu8.com/S/KMI\">$(KMI)$</a>, they added.</p>\n<p>Renewables adoption is also poised to accelerate, they said, with the demand for clean energy boosted by Biden's agenda on climate change. It could potentially lead to significant investments in existing renewable facilities and building new solar and wind farms.</p>\n<p>\"We think this bodes well for specialty contractors, such as MasTec <a href=\"https://laohu8.com/S/MTZ\">$(MTZ)$</a> and engineering and construction-focused Fluor <a href=\"https://laohu8.com/S/FLR\">$(FLR)$</a> given their expertise in clean energy infrastructure and management, as well as for General Electric <a href=\"https://laohu8.com/S/GE\">$(GE)$</a> given its wind turbine portfolio and related digital offerings,\" they said.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other long-term themes to watch out for are electric-vehicle infrastructure and green hydrogen, which is produced when renewable energy powers the electrolysis of water -- breaking it into its component elements of hydrogen and oxygen.</p>\n<p>MasTec, Rockwell Automation <a href=\"https://laohu8.com/S/ROK\">$(ROK)$</a>, 3M <a href=\"https://laohu8.com/S/MMM\">$(MMM)$</a>, Vontier <a href=\"https://laohu8.com/S/VNT\">$(VNT)$</a> and Dover Corp <a href=\"https://laohu8.com/S/DOV\">$(DOV)$</a> are all set to benefit from EV proliferation, while General Electric, Emerson Electric <a href=\"https://laohu8.com/S/EMR\">$(EMR)$</a> and KBR <a href=\"https://laohu8.com/S/KBR\">$(KBR)$</a> can capitalize on the emergence of green hydrogen, they added.</p>\n<p><b>The markets</b></p>\n<p>European stocks climbed to fresh record highs on Monday as inflation fears continued to ease. U.S. stocks were mixed in early trading . The yield on the 10-year Treasury remained anchored below 1.50%.</p>\n<p><b>The tweet</b></p>\n<p>Bitcoin jumped sharply on Sunday Chief Executive Elon Musk said the electric-vehicle company \"only\" sold around 10% of its holdings and would resume allowing transactions using the cryptocurrency when 50% of energy used to mine it comes from clean sources. Bitcoin was trading at $39,507.35 early on Friday and has climbed 11.7% in the past 24 hours, according to CoinDesk.</p>\n<p><b>The buzz</b></p>\n<p>Royal Dutch Shell is reviewing its holdings in the largest oil field in the U.S . -- the Permian Basin, mostly in Texas -- according to reports on Sunday. A sale could raise up to $10 billion, CNBC said.</p>\n<p>U.K. Prime Minister Boris Johnson is expected to confirm a four-week delay to the next planned relaxation of COVID-19 restrictions in England due to the spread of the delta coronavirus variant.</p>\n<p>Leaders of the G-7 (Group of Seven) countries rallied around Biden's call to challenge China over human rights and vowed to donate <a href=\"https://laohu8.com/S/AONE\">one</a> billion COVID-19 vaccine doses to poorer nations over the next year.</p>\n<p>Novavax <a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a> reported that a Phase 3 study of its COVID-19 vaccine showed it was 90.4% effective overall . The 29,960-patient study also found that the vaccine provided 100% protection against moderate and severe disease. The biotech intends to file for regulatory authorizations in the third quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KMI":"金德尔摩根"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143735244","content_text":"Critical information for the trading day.\n\nU.S. stocks got off to a mixed start on Monday, after the S&P 500 notched its 28th record high of the year on Friday.\nInvestors will be closely watching the Federal Reserve's latest monetary policy decision on Wednesday as well as what Chair Jerome Powell has to say .\nPresident Joe Biden's infrastructure plans are also in focus, after talks with Senate Republicans over a $1.7 trillion deal collapsed last week. Bipartisan efforts over a compromise are continuing, while a Democratic-only Reconciliation Bill is also seen as an option. Biden has set a summer deadline for Congress to pass his top legislative priority.\nIn our call of the day, Citi strategists looked at the prospects for Biden's infrastructure plans and the stocks that are likely to benefit.\nThe strategists, led by Edward Morse, said it now looked likely that passable legislation would be below the $1.7 trillion of infrastructure but higher than $1 trillion. The team looked at which areas would still make the cut in terms of spending.\n\"Enhanced policy support for carbon capture, utilization and storage (CCUS) likely survives and would have bipartisan support if a reconciliation process fails,\" they said.\nCCUS involves capturing carbon dioxide from large sources, such as power plants, and storing it to be recycled. It can play an \"important and diverse\" role in meeting global energy and climate goals, according to the International Energy Agency.\n\"The bill could jump-start an industry that could grow to be larger than today's domestic oil-and-gas industry,\" Citi strategists said. That would change the terminal value debate over companies such as Exxon Mobil $(XOM)$, which has more than 30 years of experience in CCUS, and other established names in the space, including Baker Hughes $(BKR)$, Schlumberger $(SLB)$, Chart Industries $(GTLS)$, Valero Energy $(VLO)$ and Kinder Morgan $(KMI)$, they added.\nRenewables adoption is also poised to accelerate, they said, with the demand for clean energy boosted by Biden's agenda on climate change. It could potentially lead to significant investments in existing renewable facilities and building new solar and wind farms.\n\"We think this bodes well for specialty contractors, such as MasTec $(MTZ)$ and engineering and construction-focused Fluor $(FLR)$ given their expertise in clean energy infrastructure and management, as well as for General Electric $(GE)$ given its wind turbine portfolio and related digital offerings,\" they said.\nTwo other long-term themes to watch out for are electric-vehicle infrastructure and green hydrogen, which is produced when renewable energy powers the electrolysis of water -- breaking it into its component elements of hydrogen and oxygen.\nMasTec, Rockwell Automation $(ROK)$, 3M $(MMM)$, Vontier $(VNT)$ and Dover Corp $(DOV)$ are all set to benefit from EV proliferation, while General Electric, Emerson Electric $(EMR)$ and KBR $(KBR)$ can capitalize on the emergence of green hydrogen, they added.\nThe markets\nEuropean stocks climbed to fresh record highs on Monday as inflation fears continued to ease. U.S. stocks were mixed in early trading . The yield on the 10-year Treasury remained anchored below 1.50%.\nThe tweet\nBitcoin jumped sharply on Sunday Chief Executive Elon Musk said the electric-vehicle company \"only\" sold around 10% of its holdings and would resume allowing transactions using the cryptocurrency when 50% of energy used to mine it comes from clean sources. Bitcoin was trading at $39,507.35 early on Friday and has climbed 11.7% in the past 24 hours, according to CoinDesk.\nThe buzz\nRoyal Dutch Shell is reviewing its holdings in the largest oil field in the U.S . -- the Permian Basin, mostly in Texas -- according to reports on Sunday. A sale could raise up to $10 billion, CNBC said.\nU.K. Prime Minister Boris Johnson is expected to confirm a four-week delay to the next planned relaxation of COVID-19 restrictions in England due to the spread of the delta coronavirus variant.\nLeaders of the G-7 (Group of Seven) countries rallied around Biden's call to challenge China over human rights and vowed to donate one billion COVID-19 vaccine doses to poorer nations over the next year.\nNovavax $(NVAX)$ reported that a Phase 3 study of its COVID-19 vaccine showed it was 90.4% effective overall . The 29,960-patient study also found that the vaccine provided 100% protection against moderate and severe disease. The biotech intends to file for regulatory authorizations in the third quarter.","news_type":1,"symbols_score_info":{"KMI":0.9}},"isVote":1,"tweetType":1,"viewCount":1226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187487175,"gmtCreate":1623762092597,"gmtModify":1703818489089,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"shiyotham","avatar":"https://community-static.tradeup.com/news/ffd7475c753c52dc5527673c8bc28362","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Yes to effective vaccines!","listText":"Yes to effective vaccines!","text":"Yes to effective vaccines!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187487175","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://ttm.financial/m/news/1167457915?lang=en_US&edition=fundamental","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for <b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b> Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b> The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b> The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b> Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b> Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for <b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b> Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b> The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b> The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b> Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b> Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188107168,"gmtCreate":1623423185554,"gmtModify":1704203377319,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"shiyotham","avatar":"https://community-static.tradeup.com/news/ffd7475c753c52dc5527673c8bc28362","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"? ?? ","listText":"? ?? ","text":"? ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188107168","repostId":"1189985902","repostType":4,"isVote":1,"tweetType":1,"viewCount":1196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188913037,"gmtCreate":1623419165329,"gmtModify":1704203135418,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"shiyotham","avatar":"https://community-static.tradeup.com/news/ffd7475c753c52dc5527673c8bc28362","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Nio ftw ??","listText":"Nio ftw ??","text":"Nio ftw ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188913037","repostId":"1146386859","repostType":4,"isVote":1,"tweetType":1,"viewCount":1307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114266217,"gmtCreate":1623075922339,"gmtModify":1704195598962,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"shiyotham","avatar":"https://community-static.tradeup.com/news/ffd7475c753c52dc5527673c8bc28362","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"The next GameStop!","listText":"The next GameStop!","text":"The next GameStop!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114266217","repostId":"2141286115","repostType":4,"isVote":1,"tweetType":1,"viewCount":1434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114268935,"gmtCreate":1623075846227,"gmtModify":1704195596995,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"shiyotham","avatar":"https://community-static.tradeup.com/news/ffd7475c753c52dc5527673c8bc28362","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"[Doubt] ","listText":"[Doubt] ","text":"[Doubt]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114268935","repostId":"1126396501","repostType":4,"isVote":1,"tweetType":1,"viewCount":1123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}